Skip to main content

4 Result(s)

within Amy L. Cummings Remove this filter

and

  1. No Access

    Chapter

    Acute Myeloid Leukemia: Mutations Blocking Differentiation Lead to Distinct Leukemic Subtypes

    A 70-year-old African-American male presented to the emergency room for 1 month of fatigue, progressive dyspnea on exertion, and easy bruising. He endorsed a past medical history significant for insulin-depend...

    Amy L. Cummings, Darren Pan, Gary J. Schiller in Human Pathobiochemistry (2019)

  2. No Access

    Article

    Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44

    Human leukocyte antigen (HLA)-B has been recognized as a major determinant of discrepancies in disease outcomes, and recent evidence indicates a role in immune checkpoint blockade (ICB) efficacy. The B44 super...

    Amy L. Cummings, Jaklin Gukasyan, Henry Y. Lu, Tristan Grogan… in Nature Cancer (2020)

  3. Article

    Open Access

    Comparison of the tumor immune microenvironment and checkpoint blockade biomarkers between stage III and IV non-small cell lung cancer

    Adjuvant immune checkpoint blockade (ICB) following chemoradiotherapy and adding ICB to chemotherapy have been key advances for stages III-IV non-small cell lung cancer (NSCLC) treatment. However, known biomar...

    Yinjie Gao, Michelle M. Stein, Matthew Kase… in Cancer Immunology, Immunotherapy (2023)

    Download PDF (2983 KB) View Article

  4. No Access

    Article

    Consent document translation expense hinders inclusive clinical trial enrolment

    Patients from historically under-represented racial and ethnic groups are enrolled in cancer clinical trials at disproportionately low rates in the USA1–3. As these patients often have limited English proficiency

    Maria A. Velez, Beth A. Glenn, Maria Garcia-Jimenez, Amy L. Cummings… in Nature (2023)